Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug

Fineline Cube Jun 11, 2024

Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...

Policy / Regulatory

China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024

Fineline Cube Jun 11, 2024

The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...

Company Drug

Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth

Fineline Cube Jun 11, 2024

Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its...

Company

Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center

Fineline Cube Jun 11, 2024

Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a...

Company Drug

Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial

Fineline Cube Jun 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...

Company Drug

AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC

Fineline Cube Jun 11, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...

Company Deals

MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...

Company Deals

GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million

Fineline Cube Jun 7, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the...

Policy / Regulatory

Four More Chinese Provinces Include ART in Medical Insurance Payment System

Fineline Cube Jun 7, 2024

The provincial governments of Jiangxi, Shanghai, Qinghai, and Zhejiang have added assisted reproductive technology (ART)...

Company Legal / IP

J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million

Fineline Cube Jun 7, 2024

Johnson & Johnson (J&J; NYSE: JNJ) suffered a defeat in a US court this week,...

Company

MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...

Policy / Regulatory

China Unveils Ambitious 2024 Medical Reforms with Increased Investment and Policy Reforms

Fineline Cube Jun 7, 2024

The State Council has issued a notification outlining key medical system reforms for 2024, aiming...

Company

Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration

Fineline Cube Jun 7, 2024

Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set...

Company Medical Device

Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval

Fineline Cube Jun 7, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Medical Device

MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter

Fineline Cube Jun 7, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Drug

Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment

Fineline Cube Jun 7, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...

Company Drug

Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis

Fineline Cube Jun 7, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan

Fineline Cube Jun 7, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Drug

HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies

Fineline Cube Jun 7, 2024

HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...

Company Deals

Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization

Fineline Cube Jun 6, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...

Posts pagination

1 … 343 344 345 … 661

Recent updates

  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
  • Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Others

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.